Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient

Sabrina Basso, Marco Zecca, Lucia Calafiore, Laura Rubert, Roberto Fiocchi, Marco Paulli, Giuseppe Quartuccio, Ilaria Guido, Roberta Sebastiani, Giorgio Alberto Croci, Claudia Beschi, Ida Nardiello, Fabrizio Ginevri, Chiara Cugno, Patrizia Comoli

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

CHL type is the least common major form of EBV-related PTLD but rarely occurs in pediatric recipients; development of CHL subsequent to other PTLD subtypes in the same transplant recipient is even more unusual. Because of its rarity, indications on the best treatment strategy are limited. Patients have been mostly treated with standard HL chemotherapy/radiotherapy, and prognosis seems more favorable than other monomorphic PTLDs. Herein, we describe a pediatric case of EBV-associated, stage IV-B, CHL arising in a heart allograft recipient eight yr after diagnosis of B-cell polymorphic PTLD. The patient was successfully treated with adjusted-dose HL chemotherapy and autologous EBV-specific CTL, without discontinuation of maintenance immunosuppression. At two yr from therapy completion, the patient is in CR with stable organ function. With this strategy, it may be possible to reproduce the good prognostic data reported for CHL-type PTLD, with decreased risk of organ toxicity or rejection.

Original languageEnglish
JournalPediatric Transplantation
Volume17
Issue number7
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Lymphoproliferative Disorders
Cytotoxic T-Lymphocytes
Human Herpesvirus 4
Hodgkin Disease
Pediatrics
Transplants
Drug Therapy
Immunosuppression
Allografts
B-Lymphocytes
Radiotherapy
Therapeutics
Maintenance
Transplant Recipients

Keywords

  • cytotoxic T lymphocytes
  • Epstein-Barr virus
  • lymphoproliferative disorder
  • pediatric heart transplant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this

@article{c6da66ae5d1a4d9d9bac5631b5c95c3b,
title = "Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient",
abstract = "CHL type is the least common major form of EBV-related PTLD but rarely occurs in pediatric recipients; development of CHL subsequent to other PTLD subtypes in the same transplant recipient is even more unusual. Because of its rarity, indications on the best treatment strategy are limited. Patients have been mostly treated with standard HL chemotherapy/radiotherapy, and prognosis seems more favorable than other monomorphic PTLDs. Herein, we describe a pediatric case of EBV-associated, stage IV-B, CHL arising in a heart allograft recipient eight yr after diagnosis of B-cell polymorphic PTLD. The patient was successfully treated with adjusted-dose HL chemotherapy and autologous EBV-specific CTL, without discontinuation of maintenance immunosuppression. At two yr from therapy completion, the patient is in CR with stable organ function. With this strategy, it may be possible to reproduce the good prognostic data reported for CHL-type PTLD, with decreased risk of organ toxicity or rejection.",
keywords = "cytotoxic T lymphocytes, Epstein-Barr virus, lymphoproliferative disorder, pediatric heart transplant",
author = "Sabrina Basso and Marco Zecca and Lucia Calafiore and Laura Rubert and Roberto Fiocchi and Marco Paulli and Giuseppe Quartuccio and Ilaria Guido and Roberta Sebastiani and Croci, {Giorgio Alberto} and Claudia Beschi and Ida Nardiello and Fabrizio Ginevri and Chiara Cugno and Patrizia Comoli",
year = "2013",
month = "11",
doi = "10.1111/petr.12146",
language = "English",
volume = "17",
journal = "Pediatric Transplantation",
issn = "1397-3142",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Successful treatment of a classic Hodgkin lymphoma-type post-transplant lymphoproliferative disorder with tailored chemotherapy and Epstein-Barr virus-specific cytotoxic T lymphocytes in a pediatric heart transplant recipient

AU - Basso, Sabrina

AU - Zecca, Marco

AU - Calafiore, Lucia

AU - Rubert, Laura

AU - Fiocchi, Roberto

AU - Paulli, Marco

AU - Quartuccio, Giuseppe

AU - Guido, Ilaria

AU - Sebastiani, Roberta

AU - Croci, Giorgio Alberto

AU - Beschi, Claudia

AU - Nardiello, Ida

AU - Ginevri, Fabrizio

AU - Cugno, Chiara

AU - Comoli, Patrizia

PY - 2013/11

Y1 - 2013/11

N2 - CHL type is the least common major form of EBV-related PTLD but rarely occurs in pediatric recipients; development of CHL subsequent to other PTLD subtypes in the same transplant recipient is even more unusual. Because of its rarity, indications on the best treatment strategy are limited. Patients have been mostly treated with standard HL chemotherapy/radiotherapy, and prognosis seems more favorable than other monomorphic PTLDs. Herein, we describe a pediatric case of EBV-associated, stage IV-B, CHL arising in a heart allograft recipient eight yr after diagnosis of B-cell polymorphic PTLD. The patient was successfully treated with adjusted-dose HL chemotherapy and autologous EBV-specific CTL, without discontinuation of maintenance immunosuppression. At two yr from therapy completion, the patient is in CR with stable organ function. With this strategy, it may be possible to reproduce the good prognostic data reported for CHL-type PTLD, with decreased risk of organ toxicity or rejection.

AB - CHL type is the least common major form of EBV-related PTLD but rarely occurs in pediatric recipients; development of CHL subsequent to other PTLD subtypes in the same transplant recipient is even more unusual. Because of its rarity, indications on the best treatment strategy are limited. Patients have been mostly treated with standard HL chemotherapy/radiotherapy, and prognosis seems more favorable than other monomorphic PTLDs. Herein, we describe a pediatric case of EBV-associated, stage IV-B, CHL arising in a heart allograft recipient eight yr after diagnosis of B-cell polymorphic PTLD. The patient was successfully treated with adjusted-dose HL chemotherapy and autologous EBV-specific CTL, without discontinuation of maintenance immunosuppression. At two yr from therapy completion, the patient is in CR with stable organ function. With this strategy, it may be possible to reproduce the good prognostic data reported for CHL-type PTLD, with decreased risk of organ toxicity or rejection.

KW - cytotoxic T lymphocytes

KW - Epstein-Barr virus

KW - lymphoproliferative disorder

KW - pediatric heart transplant

UR - http://www.scopus.com/inward/record.url?scp=84885433973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885433973&partnerID=8YFLogxK

U2 - 10.1111/petr.12146

DO - 10.1111/petr.12146

M3 - Article

VL - 17

JO - Pediatric Transplantation

JF - Pediatric Transplantation

SN - 1397-3142

IS - 7

ER -